Barbara Adams Krolak: Do GLP-1s Affect Blood Clot Risk?
Barbara Adams Krolak, Marketing Manager at ISTH, shared International Society on Thrombosis and Haemostasis (ISTH)‘s post on LinkedIn, adding:
“We are very excited to drop this new episode of the ISTH Pulse Podcast that explores a trending question we’re hearing: Do GLP-1s affect blood clot risk?
Listen now to hear what the experts have to say about this.”
International Society on Thrombosis and Haemostasis (ISTH) shared a post on LinkedIn:
“GLP-1 receptor agonists are increasingly used in the treatment of type 2 diabetes and obesity, but what do we know about their potential relationship with venous thromboembolism (VTE)?
Tune in to a special episode, presented in collaboration with Vasculearn Network, to hear host Julia Sandrin Gauer joined by Dr. Christian Ruff and Dr. Rushad Patell to discuss the latest evidence, unanswered questions and practical considerations for clinicians, including:
- Potential effects on clotting risk
- The roles of weight loss and cardiometabolic health
- Anti-inflammatory mechanisms
- Differences across GLP-1 and dual GIP/GLP-1 therapies
- Gaps in the current evidence.
Listen now and let us know what you think.”

Stay updated with Hemostasis Today.
-
Sep 17, 2026, 16:30Daria Camilli: Empowering Bleeding Disorder Advocacy Through Health Economics
-
Sep 17, 2026, 16:17Mehran Ghasemzadeh: Platelet NK Cell Crosstalk in Advanced Coronary Artery Disease
-
Sep 17, 2026, 15:46Heghine Khachatryan: Clinical Context at the Core of Thrombosis and Thrombophilia Management
-
Sep 17, 2026, 15:33Alexandros Makis: When Microcytic Anemia Has an Inherited Cause
-
Sep 17, 2026, 15:22α2-Antiplasmin Inhibition and the Future of Thrombolysis
-
Sep 17, 2026, 15:20Fatma M. Attia: Expanding the Evidence Base for Therapeutic Plasma Exchange Across Multiple Indications
-
Sep 17, 2026, 15:19Conan McIlwrath: The Haemophilia Society Engages With IBCA
-
Sep 17, 2026, 15:06Eleftheria Hatzimichael: A Contemporary Diagnostic Approach to Inherited Microcytic Anemias
-
Sep 17, 2026, 14:51Konstantin Yenkoyan: Emicizumab and the Power of Translational Science